Hologic Inc Financials
This page shows Hologic Inc (HOLX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Hologic runs a low-capex, high-cash-conversion model whose earnings are being shaped more by margin reset than by revenue movement.
From FY2023 to FY2025, revenue stayed pinned near$4.0B while operating margin only partly recovered, ending FY2025 at17.4% . Because SG&A rose to$449.3M even as gross margin eased to51.7% , the latest profit pressure looks more like a cost-structure issue than a fresh volume shock.
FY2025 operating cash flow of
Liquidity looks comfortable: cash of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Hologic Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Hologic Inc has an operating margin of 17.4%, meaning the company retains $17 of operating profit per $100 of revenue. This strong profitability earns a score of 78/100, reflecting efficient cost management and pricing power. This is down from 21.9% the prior year.
Hologic Inc's revenue grew a modest 1.7% year-over-year to $4.1B. This slow but positive growth earns a score of 35/100.
Hologic Inc has a moderate D/E ratio of 0.50. This balance of debt and equity financing earns a leverage score of 59/100.
With a current ratio of 3.75, Hologic Inc holds $3.75 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 84/100.
Hologic Inc converts 24.3% of revenue into free cash flow ($998.3M). This strong cash generation earns a score of 92/100.
Hologic Inc's ROE of 11.2% shows moderate profitability relative to equity, earning a score of 61/100. This is down from 15.4% the prior year.
Hologic Inc scores 4.17, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($17.0B) relative to total liabilities ($4.0B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Hologic Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Hologic Inc generates $1.87 in operating cash flow ($1.1B OCF vs $565.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Hologic Inc earns $6.1 in operating income for every $1 of interest expense ($714.3M vs $117.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Hologic Inc generated $4.1B in revenue in fiscal year 2025. This represents an increase of 1.7% from the prior year.
Hologic Inc's EBITDA was $1.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.9% from the prior year.
Hologic Inc reported $565.7M in net income in fiscal year 2025. This represents a decrease of 28.3% from the prior year.
Hologic Inc earned $2.49 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 25.0% from the prior year.
Cash & Balance Sheet
Hologic Inc generated $998.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 17.7% from the prior year.
Hologic Inc held $2.0B in cash against $2.5B in long-term debt as of fiscal year 2025.
Hologic Inc had 223M shares outstanding in fiscal year 2025.
Margins & Returns
Hologic Inc's gross margin was 51.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.6 percentage points from the prior year.
Hologic Inc's operating margin was 17.4% in fiscal year 2025, reflecting core business profitability. This is down 4.5 percentage points from the prior year.
Hologic Inc's net profit margin was 13.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 5.8 percentage points from the prior year.
Hologic Inc's ROE was 11.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.2 percentage points from the prior year.
Capital Allocation
Hologic Inc invested $248.2M in research and development in fiscal year 2025. This represents a decrease of 9.0% from the prior year.
Hologic Inc spent $752.9M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 9.8% from the prior year.
Hologic Inc invested $58.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 18.8% from the prior year.
HOLX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B-0.2% | $1.0B+2.5% | $1.0B+1.8% | $1.0B-1.6% | $1.0B+3.4% | $988.0M-2.3% | $1.0B-0.6% | $1.0B |
| Cost of Revenue | $417.6M | N/A | N/A | N/A | $392.0M | N/A | N/A | $308.6M |
| Gross Profit | $586.4M+0.5% | $583.5M+1.2% | $576.6M+52.8% | $377.3M-35.0% | $580.5M+4.1% | $557.7M-0.5% | $560.3M+3.3% | $542.3M |
| R&D Expenses | $60.5M-6.9% | $65.0M+5.9% | $61.4M-0.2% | $61.5M+2.0% | $60.3M-10.4% | $67.3M+5.0% | $64.1M-14.1% | $74.6M |
| SG&A Expenses | $127.8M+11.3% | $114.8M+15.8% | $99.1M-17.2% | $119.7M+3.5% | $115.7M+12.1% | $103.2M+9.8% | $94.0M-6.4% | $100.4M |
| Operating Income | $237.0M0.0% | $236.9M-7.0% | $254.6M+3737.1% | -$7.0M-103.0% | $229.8M-0.1% | $230.0M-5.7% | $244.0M+16.0% | $210.4M |
| Interest Expense | $27.6M-3.5% | $28.6M-1.0% | $28.9M-0.7% | $29.1M-4.6% | $30.5M-4.4% | $31.9M0.0% | $31.9M-1.2% | $32.3M |
| Income Tax | $50.6M+26.5% | $40.0M-0.2% | $40.1M+461.3% | -$11.1M-123.9% | $46.5M+8.1% | $43.0M-6.9% | $46.2M+11.1% | $41.6M |
| Net Income | $179.1M-4.3% | $187.2M-4.0% | $194.9M+1220.1% | -$17.4M-108.7% | $201.0M+12.5% | $178.6M-8.2% | $194.5M+14.5% | $169.9M |
| EPS (Diluted) | $0.79 | N/A | $0.86+1175.0% | $-0.08-109.2% | $0.87 | N/A | $0.82+13.9% | $0.72 |
HOLX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.2B+1.8% | $9.0B+2.4% | $8.8B+3.1% | $8.5B-2.1% | $8.7B-4.7% | $9.2B+3.0% | $8.9B+2.0% | $8.7B |
| Current Assets | $3.8B+4.8% | $3.7B+7.2% | $3.4B+6.6% | $3.2B-8.2% | $3.5B-8.6% | $3.8B-4.3% | $4.0B+5.5% | $3.8B |
| Cash & Equivalents | $2.2B+10.6% | $2.0B+12.9% | $1.7B+21.4% | $1.4B-19.8% | $1.8B-17.5% | $2.2B-11.4% | $2.4B+11.9% | $2.2B |
| Inventory | $688.5M+1.3% | $679.4M-4.8% | $713.7M-0.4% | $716.7M+1.4% | $707.1M+4.0% | $679.8M+2.1% | $665.5M+2.5% | $649.2M |
| Accounts Receivable | $584.2M-2.8% | $600.8M-1.4% | $609.3M-5.4% | $644.4M+2.1% | $631.4M+5.2% | $600.4M-4.5% | $628.5M-2.9% | $647.1M |
| Goodwill | $3.6B+0.1% | $3.6B-0.1% | $3.6B+0.5% | $3.6B+5.9% | $3.4B-0.6% | $3.4B+4.6% | $3.3B0.0% | $3.3B |
| Total Liabilities | $3.9B-0.8% | $4.0B+0.1% | $4.0B+0.9% | $3.9B-0.7% | $4.0B-1.8% | $4.0B+2.2% | $3.9B+1.8% | $3.9B |
| Current Liabilities | $951.3M-2.7% | $977.2M+1.5% | $962.5M-2.7% | $989.7M-1.3% | $1.0B-3.4% | $1.0B+3.5% | $1.0B+5.0% | $954.6M |
| Long-Term Debt | $2.5B-0.1% | $2.5B-0.2% | $2.5B+1.9% | $2.5B-0.7% | $2.5B-0.7% | $2.5B-0.3% | $2.5B-0.3% | $2.5B |
| Total Equity | $5.2B+3.9% | $5.0B+4.2% | $4.8B+4.8% | $4.6B-3.2% | $4.8B-7.0% | $5.1B+3.6% | $5.0B+2.2% | $4.8B |
| Retained Earnings | $3.6B+5.2% | $3.4B+5.8% | $3.2B+6.4% | $3.0B-0.6% | $3.0B+7.1% | $2.8B+6.7% | $2.7B+7.9% | $2.5B |
HOLX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $229.9M-35.3% | $355.1M+3.4% | $343.3M+102.7% | $169.4M-10.5% | $189.3M-48.4% | $367.0M-9.6% | $405.8M+38.8% | $292.4M |
| Capital Expenditures | $14.7M+7.3% | $13.7M-60.7% | $34.9M-13.4% | $40.3M+139.9% | $16.8M+2.4% | $16.4M-51.6% | $33.9M+21.1% | $28.0M |
| Free Cash Flow | $215.2M-37.0% | $341.4M+10.7% | $308.4M+138.9% | $129.1M-25.2% | $172.5M-50.8% | $350.6M-5.7% | $371.9M+40.7% | $264.4M |
| Investing Cash Flow | -$12.1M+90.8% | -$132.1M-2972.1% | -$4.3M+98.7% | -$324.3M-1374.1% | -$22.0M+96.3% | -$595.7M-1298.4% | -$42.6M-10.6% | -$38.5M |
| Financing Cash Flow | -$10.7M-768.8% | $1.6M+104.0% | -$40.1M+80.1% | -$201.7M+62.4% | -$537.0M-845.4% | -$56.8M+45.3% | -$103.8M-2371.4% | -$4.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0-100.0% | $35.6M-82.2% | $200.0M-61.3% | $517.3M+787.3% | $58.3M-41.7% | $100.0M | $0 |
HOLX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.0%+0.4pp | 55.6%-0.7pp | 56.3%+18.8pp | 37.5%-19.3pp | 56.8%+0.4pp | 56.5%+1.0pp | 55.4%+2.1pp | 53.3% |
| Operating Margin | 22.6%+0.1pp | 22.6%-2.3pp | 24.9%+25.6pp | -0.7%-23.2pp | 22.5%-0.8pp | 23.3%-0.8pp | 24.1%+3.5pp | 20.7% |
| Net Margin | 17.1%-0.8pp | 17.8%-1.2pp | 19.0%+20.8pp | -1.7%-21.4pp | 19.7%+1.6pp | 18.1%-1.2pp | 19.2%+2.5pp | 16.7% |
| Return on Equity | 3.4%-0.3pp | 3.7%-0.3pp | 4.0%+4.4pp | -0.4%-4.6pp | 4.2%+0.7pp | 3.5%-0.5pp | 3.9%+0.4pp | 3.5% |
| Return on Assets | 1.9%-0.1pp | 2.1%-0.1pp | 2.2%+2.4pp | -0.2%-2.5pp | 2.3%+0.3pp | 1.9%-0.2pp | 2.2%+0.2pp | 1.9% |
| Current Ratio | 4.04+0.3 | 3.75+0.2 | 3.55+0.3 | 3.24-0.2 | 3.49-0.2 | 3.69-0.3 | 3.99+0.0 | 3.97 |
| Debt-to-Equity | 0.48-0.0 | 0.50-0.0 | 0.52-0.0 | 0.53+0.0 | 0.52+0.0 | 0.49-0.0 | 0.51-0.0 | 0.52 |
| FCF Margin | 20.5%-12.0pp | 32.5%+2.4pp | 30.1%+17.3pp | 12.8%-4.0pp | 16.9%-18.6pp | 35.5%-1.3pp | 36.8%+10.8pp | 26.0% |
Similar Companies
Frequently Asked Questions
What is Hologic Inc's annual revenue?
Hologic Inc (HOLX) reported $4.1B in total revenue for fiscal year 2025. This represents a 1.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Hologic Inc's revenue growing?
Hologic Inc (HOLX) revenue grew by 1.7% year-over-year, from $4.0B to $4.1B in fiscal year 2025.
Is Hologic Inc profitable?
Yes, Hologic Inc (HOLX) reported a net income of $565.7M in fiscal year 2025, with a net profit margin of 13.8%.
What is Hologic Inc's EBITDA?
Hologic Inc (HOLX) had EBITDA of $1.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Hologic Inc have?
As of fiscal year 2025, Hologic Inc (HOLX) had $2.0B in cash and equivalents against $2.5B in long-term debt.
What is Hologic Inc's gross margin?
Hologic Inc (HOLX) had a gross margin of 51.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Hologic Inc's operating margin?
Hologic Inc (HOLX) had an operating margin of 17.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Hologic Inc's net profit margin?
Hologic Inc (HOLX) had a net profit margin of 13.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Hologic Inc's return on equity (ROE)?
Hologic Inc (HOLX) has a return on equity of 11.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Hologic Inc's free cash flow?
Hologic Inc (HOLX) generated $998.3M in free cash flow during fiscal year 2025. This represents a -17.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Hologic Inc's operating cash flow?
Hologic Inc (HOLX) generated $1.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Hologic Inc's total assets?
Hologic Inc (HOLX) had $9.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Hologic Inc's capital expenditures?
Hologic Inc (HOLX) invested $58.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Hologic Inc spend on research and development?
Hologic Inc (HOLX) invested $248.2M in research and development during fiscal year 2025.
What is Hologic Inc's current ratio?
Hologic Inc (HOLX) had a current ratio of 3.75 as of fiscal year 2025, which is generally considered healthy.
What is Hologic Inc's debt-to-equity ratio?
Hologic Inc (HOLX) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Hologic Inc's return on assets (ROA)?
Hologic Inc (HOLX) had a return on assets of 6.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Hologic Inc's Altman Z-Score?
Hologic Inc (HOLX) has an Altman Z-Score of 4.17, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Hologic Inc's Piotroski F-Score?
Hologic Inc (HOLX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Hologic Inc's earnings high quality?
Hologic Inc (HOLX) has an earnings quality ratio of 1.87x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Hologic Inc cover its interest payments?
Hologic Inc (HOLX) has an interest coverage ratio of 6.1x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Hologic Inc?
Hologic Inc (HOLX) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.